Resistance to oncolytic virotherapy: Multidimensional mechanisms and therapeutic breakthroughs (Review)

Siegel RL, Kratzer TB, Giaquinto AN, Sung H and Jemal A: Cancer statistics, 2025. CA Cancer J Clin. 75:10–45. 2025.PubMed/NCBI

Pol J, Buqué A, Aranda F, Bloy N, Cremer I, Eggermont A, Erbs P, Fucikova J, Galon J, Limacher JM, et al: Trial watch-oncolytic viruses and cancer therapy. Oncoimmunology. 5:e11177402016. View Article : Google Scholar : PubMed/NCBI

Dagogo-Jack I and Shaw AT: Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol. 15:81–94. 2018. View Article : Google Scholar

Ma R, Li Z, Chiocca EA, Caligiuri MA and Yu J: The emerging field of oncolytic virus-based cancer immunotherapy. Trends Cancer. 9:122–139. 2023. View Article : Google Scholar :

Nandi SS, Gohil T, Sawant SA, Lambe UP, Ghosh S and Jana S: CD155: A key receptor playing diversified roles. Curr Mol Med. 22:594–607. 2022. View Article : Google Scholar

Kučan Brlić P, Lenac Roviš T, Cinamon G, Tsukerman P, Mandelboim O and Jonjić S: Targeting PVR (CD155) and its receptors in anti-tumor therapy. Cell Mol Immunol. 16:40–52. 2019. View Article : Google Scholar

Yang M, Yang CS, Guo W, Tang J, Huang Q, Feng S, Jiang A, Xu X, Jiang G and Liu YQ: A novel fiber chimeric conditionally replicative adenovirus-Ad5/F35 for tumor therapy. Cancer Biol Ther. 18:833–840. 2017. View Article : Google Scholar : PubMed/NCBI

Phung AT, Shah JR, Dong T, Reid T, Larson C, Sanchez AB, Oronsky B, Trogler WC, Kummel AC, Aisagbonhi O and Blair SL: CAR expression in invasive breast carcinoma and its effect on adenovirus transduction efficiency. Breast Cancer Res. 26:1312024. View Article : Google Scholar : PubMed/NCBI

Scheicher NV, Berchtold S, Beil J, Smirnow I, Schenk A and Lauer UM: In vitro sensitivity of neuroendocrine neoplasms to an armed oncolytic measles vaccine virus. Cancers (Basel). 16:4882024. View Article : Google Scholar : PubMed/NCBI

Cao W, Tian J, Li C, Gao Y, Liu X, Lu J, Wang Y, Wang Z, Svatek RS and Rodriguez R: A novel bladder cancer-specific oncolytic adenovirus by CD46 and its effect combined with cisplatin against cancer cells of CAR negative expression. Virol J. 14:1492017. View Article : Google Scholar

Lipatova AV, Le TH, Sosnovtseva AO, Babaeva FE, Kochetkov DV and Chumakov PM: Relationship between cell receptors and tumor cell sensitivity to oncolytic enteroviruses. Bull Exp Biol Med. 166:58–62. 2018. View Article : Google Scholar : PubMed/NCBI

Schäfer TE, Knol LI, Haas FV, Hartley A, Pernickel SCS, Jády A, Finkbeiner MSC, Achberger J, Arelaki S, Modic Ž, et al: Biomarker screen for efficacy of oncolytic virotherapy in patient-derived pancreatic cancer cultures. EBioMedicine. 105:1052192024. View Article : Google Scholar : PubMed/NCBI

Felt SA, Droby GN and Grdzelishvili VZ: Ruxolitinib and polycation combination treatment overcomes multiple mechanisms of resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus. J Virol. 91:e00461–17. 2017. View Article : Google Scholar : PubMed/NCBI

Yaiw KC, Miest TS, Frenzke M, Timm M, Johnston PB and Cattaneo R: CD20-targeted measles virus shows high oncolytic specificity in clinical samples from lymphoma patients independent of prior rituximab therapy. Gene Ther. 18:313–317. 2011. View Article : Google Scholar

Ingusci S, Hall BL, Cohen JB and Glorioso JC: Oncolytic herpes simplex viruses designed for targeted treatment of EGFR-bearing tumors. Mol Ther Oncol. 32:2007612024. View Article : Google Scholar : PubMed/NCBI

Leoni V, Vannini A, Gatta V, Rambaldi J, Sanapo M, Barboni C, Zaghini A, Nanni P, Lollini PL, Casiraghi C and Campadelli-Fiume G: A fully-virulent retargeted oncolytic HSV armed with IL-12 elicits local immunity and vaccine therapy towards distant tumors. PLoS Pathog. 14:e10072092018. View Article : Google Scholar : PubMed/NCBI

Shiao SL, Gouin KH III, Ing N, Ho A, Basho R, Shah A, Mebane RH, Zitser D, Martinez A, Mevises NY, et al: Single-cell and spatial profiling identify three response trajectories to pembrolizumab and radiation therapy in triple negative breast cancer. Cancer Cell. 42:70–84.e8. 2024. View Article : Google Scholar : PubMed/NCBI

MacLeod DT, Nakatsuji T, Yamasaki K, Kobzik L and Gallo RL: HSV-1 exploits the innate immune scavenger receptor MARCO to enhance epithelial adsorption and infection. Nat Commun. 4:19632013. View Article : Google Scholar : PubMed/NCBI

MacLeod DT, Nakatsuji T, Wang Z, di Nardo A and Gallo RL: Vaccinia virus binds to the scavenger receptor MARCO on the surface of keratinocytes. J Invest Dermatol. 135:142–150. 2015. View Article : Google Scholar

Stichling N, Suomalainen M, Flatt JW, Schmid M, Pacesa M, Hemmi S, Jungraithmayr W, Maler MD, Freudenberg MA, Plückthun A, et al: Lung macrophage scavenger receptor SR-A6 (MARCO) is an adenovirus type-specific virus entry receptor. PLoS Pathog. 14:e10069142018. View Article : Google Scholar : PubMed/NCBI

Ghosh S, Gregory D, Smith A and Kobzik L: MARCO regulates early inflammatory responses against influenza: A useful macrophage function with adverse outcome. Am J Respir Cell Mol Biol. 45:1036–1044. 2011. View Article : Google Scholar : PubMed/NCBI

Carpentier KS, Sheridan RM, Lucas CJ, Davenport BJ, Li FS, Lucas ED, McCarthy MK, Reynoso GV, May NA, Tamburini BAJ, et al: MARCO(+) lymphatic endothelial cells sequester arthritogenic alphaviruses to limit viremia and viral dissemination. EMBO J. 40:e1089662021. View Article : Google Scholar : PubMed/NCBI

High M, Cho HY, Marzec J, Wiltshire T, Verhein KC, Caballero MT, Caballero MT, Acosta PL, Ciencewicki J, McCaw ZR, et al: Determinants of host susceptibility to murine respiratory syncytial virus (RSV) disease identify a role for the innate immunity scavenger receptor MARCO gene in human infants. EBioMedicine. 11:73–84. 2016. View Article : Google Scholar : PubMed/NCBI

Ayala-Breton C, Barber GN, Russell SJ and Peng KW: Retargeting vesicular stomatitis virus using measles virus envelope glycoproteins. Hum Gene Ther. 23:484–491. 2012. View Article : Google Scholar :

Dan J, Cai J, Zhong Y, Wang C, Huang S, Zeng Y, Fan Z, Xu C, Hu L, Zhang J, et al: Oncolytic virus M1 functions as a bifunctional checkpoint inhibitor to enhance the antitumor activity of DC vaccine. Cell Rep Med. 4:1012292023. View Article : Google Scholar : PubMed/NCBI

Dong B, Tang N, Guan Y, Qu G, Miao L, Han W and Shen Z: Type and abundance of sialic acid receptors on host cell membrane affect infectivity and viral titer of different strains of Newcastle disease virus. J Virol Methods. 302:1144882022. View Article : Google Scholar : PubMed/NCBI

Haisma HJ, Grill J, Curiel DT, Hoogeland S, van Beusechem VW, Pinedo HM and Gerritsen WR: Targeting of adenoviral vectors through a bispecific single-chain antibody. Cancer Gene Ther. 7:901–904. 2000. View Article : Google Scholar : PubMed/NCBI

Hall BL, Leronni D, Miyagawa Y, Goins WF, Glorioso JC and Cohen JB: Generation of an oncolytic herpes simplex viral vector completely retargeted to the GDNF receptor GFRα1 for specific infection of breast cancer cells. Int J Mol Sci. 21:88152020. View Article : Google Scholar

Menotti L, Avitabile E, Gatta V, Malatesta P, Petrovic B and Campadelli-Fiume G: HSV as a platform for the generation of retargeted, armed, and reporter-expressing oncolytic viruses. Viruses. 10:3522018. View Article : Google Scholar : PubMed/NCBI

Merrill MK, Bernhardt G, Sampson JH, Wikstrand CJ, Bigner DD and Gromeier M: Poliovirus receptor CD155-targeted oncolysis of glioma. Neuro Oncol. 6:208–217. 2004. View Article : Google Scholar : PubMed/NCBI

O'Bryan SM and Mathis JM: CXCL12 retargeting of an oncolytic adenovirus vector to the chemokine CXCR4 and CXCR7 receptors in breast cancer. J Cancer Ther. 12:311–336. 2021. View Article : Google Scholar : PubMed/NCBI

Shibata T, Uchida H, Shiroyama T, Okubo Y, Suzuki T, Ikeda H, Yamaguchi M, Miyagawa Y, Fukuhara T, Cohen JB, et al: Development of an oncolytic HSV vector fully retargeted specifically to cellular EpCAM for virus entry and cell-to-cell spread. Gene Ther. 23:479–488. 2016. View Article : Google Scholar : PubMed/NCBI

Tian L, Xu B, Chen Y, Li Z, Wang J, Zhang J, Ma R, Cao S, Hu W, Chiocca EA, et al: Specific targeting of glioblastoma with an oncolytic virus expressing a cetuximab-CCL5 fusion protein via innate and adaptive immunity. Nat Cancer. 3:1318–1335. 2022. View Article : Google Scholar : PubMed/NCBI

Choi AH, O'Leary MP, Lu J, Kim SI, Fong Y and Chen NG: Endogenous akt activity promotes virus entry and predicts efficacy of novel chimeric orthopoxvirus in triple-negative breast cancer. Mol Ther Oncolytics. 9:22–29. 2018. View Article : Google Scholar : PubMed/NCBI

Yi KH and Lauring J: Recurrent AKT mutations in human cancers: Functional consequences and effects on drug sensitivity. Oncotarget. 7:4241–4251. 2016. View Article : Google Scholar :

Pelin A, Boulton S, Tamming LA, Bell JC and Singaravelu R: Engineering vaccinia virus as an immunotherapeutic battleship to overcome tumor heterogeneity. Expert Opin Biol Ther. 20:1083–1097. 2020. View Article : Google Scholar : PubMed/NCBI

Zeng M, Zhang W, Li Y and Yu L: Harnessing adenovirus in cancer immunotherapy: Evoking cellular immunity and targeting delivery in cell-specific manner. Biomark Res. 12:362024. View Article : Google Scholar : PubMed/NCBI

Garber K: China approves world's first oncolytic virus therapy for cancer treatment. J Natl Cancer Inst. 98:298–300. 2006. View Article : Google Scholar : PubMed/NCBI

Cheng PH, Wechman SL, McMasters KM and Zhou HS: Oncolytic replication of E1b-deleted adenoviruses. Viruses. 7:5767–5779. 2015. View Article : Google Scholar : PubMed/NCBI

Goradel NH, Mohajel N, Malekshahi ZV, Jahangiri S, Najafi M, Farhood B, Mortezaee K, Negahdari B and Arashkia A: Oncolytic adenovirus: A tool for cancer therapy in combination with other therapeutic approaches. J Cell Physiol. 234:8636–8646. 2019. View Article : Google Scholar

Abudoureyimu M, Lai Y, Tian C, Wang T, Wang R and Chu X: Oncolytic Adenovirus-A nova for gene-targeted oncolytic viral therapy in HCC. Front Oncol. 9:11822019. View Article : Google Scholar : PubMed/NCBI

Jakubczak JL, Ryan P, Gorziglia M, Clarke L, Hawkins LK, Hay C, Huang Y, Kaloss M, Marinov A, Phipps S, et al: An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy. Cancer Res. 63:1490–1499. 2003.PubMed/NCBI

Ortega S, Malumbres M and Barbacid M: Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta. 1602:73–87. 2002.PubMed/NCBI

Bracken AP, Ciro M, Cocito A and Helin K: E2F target genes: Unraveling the biology. Trends Biochem Sci. 29:409–417. 2004. View Article : Google Scholar : PubMed/NCBI

Kent LN and G: The broken cycle: E2F dysfunction in cancer. Nat Rev Cancer. 19:326–338. 2019. View Article : Google Scholar : PubMed/NCBI

Shay JW: Role of telomeres and telomerase in aging and cancer. Cancer Discov. 6:584–593. 2016. View Article : Google Scholar : PubMed/NCBI

Boccardi V and Marano L: Aging, cancer, and inflammation: The telomerase connection. Int J Mol Sci. 25:85422024. View Article : Google Scholar : PubMed/NCBI

Alfano A, Cafferata EGA, Gangemi M, Nicola Candia A, Malnero CM, Bermudez I, Lopez MV, Ríos GD, Rotondaro C, Cuneo N, et al: In vitro and in vivo efficacy of a stroma-targeted, tumor microenviron ment responsive oncolytic adenovirus in different preclinical models of cancer. Int J Mol Sci. 24:99922023. View Article : Google Scholar

Oh E, Hong J, Kwon OJ and Yun CO: A hypoxia- and telomerase-responsive oncolytic adenovirus expressing secretable trimeric TRAIL triggers tumour-specific apoptosis and promotes viral dispersion in TRAIL-resistant glioblastoma. Sci Rep. 8:14202018. View Article : Google Scholar : PubMed/NCBI

Xu C, Sun Y, Wang Y, Yan Y, Shi Z, Chen L, Lin H, Lü S, Zhu M, Su C and Li Z: CEA promoter-regulated oncolytic adenovirus-mediated Hsp70 expression in immune gene therapy for pancreatic cancer. Cancer Lett. 319:154–163. 2012. View Article : Google Scholar : PubMed/NCBI

Chouljenko DV, Murad YM, Lee IF, Delwar Z, Ding J, Liu G, Liu X, Bu X, Sun Y, Samudio I and Jia WW: Targeting carcinoembryonic antigen-expressing tumors using a novel transcriptional and translational dual-regulated oncolytic herpes simplex virus type 1. Mol Ther Oncolytics. 28:334–348. 2023. View Article : Google Scholar : PubMed/NCBI

Cho WK, Choi DH, Park HC, Park W, Yu JI, Park YS, Park JO, Lim HY, Kang WK, Kim HC, et al: Elevated CEA is associated with worse survival in recurrent rectal cancer. Oncotarget. 8:105936–105941. 2017. View Article : Google Scholar : PubMed/NCBI

Saretzki G: The telomerase connection of the brain and its implications for neurod egenerative diseases. Stem Cells. 41:233–241. 2023. View Article : Google Scholar

Aquino A, Formica V, Prete SP, Correale PP, Massara MC, Turriziani M, De Vecchis L and Bonmassar E: Drug-induced increase of carcinoembryonic antigen expression in cancer cells. Pharmacol Res. 49:383–396. 2004. View Article : Google Scholar : PubMed/NCBI

DeWeese TL, van der Poel H, Li S, Mikhak B, Drew R, Goemann M, Hamper U, DeJong R, Detorie N, Rodriguez R, et al: A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res. 61:7464–7472. 2001.PubMed/NCBI

Robert S, Roman Ortiz NI, LaRocca CJ, Ostrander JH and Davydova J: Oncolytic adenovirus for the targeting of paclitaxel-resistant breast cancer stem cells. Viruses. 16:5672024. View Article : Google Scholar : PubMed/NCBI

Denkert C, Winzer KJ, Müller BM, Weichert W, Pest S, Köbel M, Kristiansen G, Reles A, Siegert A, Guski H and Hauptmann S: Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma. Cancer. 97:2978–2987. 2003. View Article : Google Scholar : PubMed/NCBI

Hugosson J, Godtman RA, Wallstrom J, Axcrona U, Bergh A, Egevad L, Geterud K, Khatami A, Socratous A, Spyratou V, et al: Results after four years of screening for prostate cancer with PSA and MRI. N Engl J Med. 391:1083–1095. 2024. View Article : Google Scholar : PubMed/NCBI

Del Papa J, Petryk J, Bell JC and Parks RJ: An oncolytic adenovirus vector expressing p14 FAST protein induces widespread syncytium formation and reduces tumor growth rate in vivo. Mol Ther Oncolytics. 14:107–120. 2019. View Article : Google Scholar : PubMed/NCBI

Lin D, Shen Y and Liang T: Oncolytic virotherapy: Basic principles, recent advances and future directions. Signal Transduct Target Ther. 8:1562023. View Article : Google Scholar : PubMed/NCBI

Weibel S, Raab V, Yu YA, Worschech A, Wang E, Marincola FM and Szalay AA: Viral-mediated oncolysis is the most critical factor in the late-phase of the tumor regression process upon vaccinia virus infection. BMC Cancer. 11:682011. View Article : Google Scholar : PubMed/NCBI

Li W, Turaga RC, Li X, Sharma M, Enadi Z, Dunham Tompkins SN, Hardy KC, Mishra F, Tsao J, Liu ZR, et al: Overexpression of Smac by an armed vesicular stomatitis virus overcomes tumor resistance. Mol Ther Oncolytics. 14:188–195. 2019. View Article : Google Scholar : PubMed/NCBI

Dobson CC, Naing T, Beug ST, Faye MD, Chabot J, St-Jean M, Walker DE, LaCasse EC, Stojdl DF, Korneluk RG and Holcik M: Oncolytic virus synergizes with Smac mimetic compounds to induce rhabdomyosarcoma cell death in a syngeneic murine model. Oncotarget. 8:3495–3508. 2017. View Article : Google Scholar :

Zhou H, Zhang Y, Wang J, Yan Y, Liu Y, Shi X, Zhang Q and Xu X: The CREB and AP-1-dependent cell communication network factor 1 regulates porcine epidemic diarrhea virus-induced cell apoptosis inhibiting virus replication through the p53 pathway. Front Microbiol. 13:8318522022. View Article : Google Scholar : PubMed/NCBI

Mansour M, Palese P and Zamarin D: Oncolytic specificity of Newcastle disease virus is mediated by selectivity for apoptosis-resistant cells. J Virol. 85:6015–6023. 2011. View Article : Google Scholar : PubMed/NCBI

Stanziale SF, Petrowsky H, Adusumilli PS, Ben-Porat L, Gonen M and Fong Y: Infection with oncolytic herpes simplex virus-1 induces apoptosis in neighboring human cancer cells: A potential target to increase anticancer activity. Clin Cancer Res. 10:3225–3232. 2004. View Article : Google Scholar : PubMed/NCBI

Grootjans S, Vanden Berghe T and Vandenabeele P: Initiation and execution mechanisms of necroptosis: An overview. Cell Death Differ. 24:1184–1195. 2017. View Article : Google Scholar : PubMed/NCBI

Suzuki T and Uchida H: Induction of necroptosis in multinucleated giant cells induced by conditionally replicating syncytial oHSV in co-cultures of cancer cells and non-cancerous cells. Mol Ther Oncol. 32:2008032024. View Article : Google Scholar : PubMed/NCBI

Okamura K, Inoue H, Tanaka K, Ikematsu Y, Furukawa R, Ota K, Yoneshima Y, Iwama E and Okamoto I: Immunostimulatory oncolytic activity of coxsackievirus A11 in human malignant pleural mesothelioma. Cancer Sci. 114:1095–1107. 2023. View Article : Google Scholar :

Zhang J, Liu Y, Tan J, Zhang Y, Wong CW, Lin Z, Liu X, Sander M, Yang X, Liang L, et al: Necroptotic virotherapy of oncolytic alphavirus M1 cooperated with Doxorubicin displays promising therapeutic efficacy in TNBC. Oncogene. 40:4783–4795. 2021. View Article : Google Scholar : PubMed/NCBI

Van Hoecke L, Riederer S, Saelens X, Sutter G and Rojas JJ: Recombinant viruses delivering the necroptosis mediator MLKL induce a potent antitumor immunity in mice. Oncoimmunology. 9:18029682020. View Article : Google Scholar : PubMed/NCBI

Wen C, Yu Y, Gao C, Qi X, Cardona CJ and Xing Z: RIPK3-dependent necroptosis Is induced and restricts viral replication in human astrocytes infected with zika virus. Front Cell Infect Microbiol. 11:6377102021. View Article : Google Scholar : PubMed/NCBI

Gou H, Bian Z, Cai R, Chu P, Song S, Li Y, Jiang Z, Zhang K, Yang D and Li C: RIPK3-dependent necroptosis limits PRV replication in PK-15 cells. Front Microbiol. 12:6643532021. View Article : Google Scholar : PubMed/NCBI

Hu Y, Deng X, Lv Y, Liu C, Chen J, Song J and Zhang Y: Coxsackievirus-A10 induced RIPK3-driven necroptosis to promote the formation of inflammatory response and enhance virus production via being recognized by TLR3. Mol Immunol. 178:107–116. 2025. View Article : Google Scholar : PubMed/NCBI

Petrie EJ, Sandow JJ, Lehmann WIL, Liang LY, Coursier D, Young SN, Kersten WJA, Fitzgibbon C, Samson AL, Jacobsen AV, et al: Viral MLKL homologs subvert necroptotic cell death by sequestering cellular RIPK3. Cell Rep. 28:3309–3319.e5. 2019. View Article : Google Scholar : PubMed/NCBI

Deng Y, Águeda-Pinto A and Brune W: No time to die: How cytomegaloviruses suppress apoptosis, necroptosis, and pyroptosis. Viruses. 16:12722024. View Article : Google Scholar : PubMed/NCBI

van den Wollenberg DJM, Kemp V, Rabelink MJWE and Hoeben RC: Reovirus type 3 dearing variants do not induce necroptosis in RIPK3-expressing human tumor cell lines. Int J Mol Sci. 24:23202023. View Article : Google Scholar : PubMed/NCBI

Panganiban RA, Nadeau KC and Lu Q: Pyroptosis, gasdermins and allergic diseases. Allergy. 79:2380–2395. 2024. View Article : Google Scholar : PubMed/NCBI

Lin J, Sun S, Zhao K, Gao F, Wang R, Li Q, Zhou Y, Zhang J, Li Y, Wang X, et al: Oncolytic parapoxvirus induces gasdermin E-mediated pyroptosis and activates antitumor immunity. Nat Commun. 14:2242023. View Article : Google Scholar : PubMed/NCBI

Wu A, Li Z, Wang Y, Chen Y, Peng J, Zhu M, Li Y, Song H, Zhou D, Zhang C, et al: Recombinant measles virus vaccine rMV-Hu191 exerts an oncolytic effect on esophageal squamous cell carcinoma via caspase-3/GSDME-mediated pyroptosis. Cell Death Discov. 9:1712023. View Article : Google Scholar : PubMed/NCBI

Liu Z, Li Y, Zhu Y, Li N, Li W, Shang C, Song G, Li S, Cong J, Li T, et al: Apoptin induces pyroptosis of colorectal cancer cells via the GSDME-dependent pathway. Int J Biol Sci. 18:717–730. 2022. View Article : Google Scholar : PubMed/NCBI

Chen XY, Liu Y, Zhu WB, Li SH, Wei S, Cai J, Lin Y, Liang JK, Yan GM, Guo L and Hu C: Arming oncolytic M1 virus with gasdermin E enhances antitumor efficacy in breast cancer. iScience. 27:1111482024. View Article : Google Scholar : PubMed/NCBI

Wang YY, Wang J, Wang S, Yang QC, Song A, Zhang MJ, Wang WD, Liu YT, Zhang J, Wang WM, et al: Dual-responsive epigenetic inhibitor nanoprodrug combined with oncolytic virus synergistically boost cancer immunotherapy by igniting gasdermin E-mediated pyroptosis. ACS Nano. Jul 22–2024.Epub ahead of print.

Deng Y, Ostermann E and Brune W: A cytomegalovirus inflammasome inhibitor reduces proinflammatory cytokine release and pyroptosis. Nat Commun. 15:7862024. View Article : Google Scholar : PubMed/NCBI

Huang Y, Ma D, Huang H, Lu Y, Liao Y, Liu L, Liu X and Fang F: Interaction between HCMV pUL83 and human AIM2 disrupts the activation of the AIM2 inflammasome. Virol J. 14:342017. View Article : Google Scholar : PubMed/NCBI

Wang Y, Qin Y, Wang T, Chen Y, Lang X, Zheng J, Gao S, Chen S, Zhong X, Mu Y, et al: Pyroptosis induced by enterovirus 71 and coxsackievirus B3 infection affects viral replication and host response. Sci Rep. 8:28872018. View Article : Google Scholar : PubMed/NCBI

Hu Y, Zhao W, Lv Y, Li H, Li J, Zhong M, Pu D, Jian F, Song J and Zhang Y: NLRP3-dependent pyroptosis exacerbates coxsackievirus A16 and coxsackievirus A10-induced inflammatory response and viral replication in SH-SY5Y cells. Virus Res. 345:1993862024. View Article : Google Scholar : PubMed/NCBI

Jiang R, Chen D, Zhang Y, Zhou L, Ge X, Han J, Guo X and Yang H: PRRSV infection inhibits CSFV C-strain replication via GSDMD-mediated pyroptosis. Vet Microbiol. 298:1102432024. View Article : Google Scholar : PubMed/NCBI

Jiang J, Shen W, He Y, Liu J, Ouyang J, Zhang C and Hu K: Overexpression of NLRP12 enhances antiviral immunity and alleviates herpes simplex keratitis via pyroptosis/IL-18/IFN-γ signaling. Int Immunopharmacol. 137:1124282024. View Article : Google Scholar

Zhang Z, Zhang Y and Lieberman J: Lighting a fire: Can we harness pyroptosis to ignite antitumor immunity? Cancer Immunol Res. 9:2–7. 2021. View Article : Google Scholar : PubMed/NCBI

Guo ZS, Liu Z and Bartlett DL: Oncolytic immunotherapy: Dying the right way is a key to eliciting potent antitumor immunity. Front Oncol. 4:742014. View Article : Google Scholar : PubMed/NCBI

Debnath J, Gammoh N and Ryan KM: Autophagy and autophagy-related pathways in cancer. Nat Rev Mol Cell Biol. 24:560–575. 2023. View Article : Google Scholar : PubMed/NCBI

Lei W, Wang S, Xu N, Chen Y, Wu G, Zhang A, Chen X, Tong Y and Qian W: Enhancing therapeutic efficacy of oncolytic vaccinia virus armed with Beclin-1, an autophagic Gene in leukemia and myeloma. Biomed Pharmacother. 125:1100302020. View Article : Google Scholar : PubMed/NCBI

Li K, Hu C, Xing F, Gao M, Liang J, Xiao X, Cai J, Tan Y, Hu J, Zhu W, et al: Deficiency of the IRE1α-autophagy axis enhances the antitumor effects of the oncolytic virus M1. J Virol. 92:e01331–17. 2018. View Article : Google Scholar :

Xu Y, Chu L, Yuan S, Yang Y, Yang Y, Xu B, Zhang K, Liu XY, Wang R, Fang L, et al: RGD-modified oncolytic adenovirus-harboring shPKM2 exhibits a potent cytotoxic effect in pancreatic cancer via autophagy inhibition and apoptosis promotion. Cell Death Dis. 8:e28352017. View Article : Google Scholar : PubMed/NCBI

Botta G, Passaro C, Libertini S, Abagnale A, Barbato S, Maione AS, Hallden G, Beguinot F, Formisano P and Portella G: Inhibition of autophagy enhances the effects of E1A-defective oncolytic adenovirus dl922-947 against glioma cells in vitro and in vivo. Hum Gene Ther. 23:623–634. 2012. View Article : Google Scholar : PubMed/NCBI

Chen F, Lang L, Yang J, Yang F, Tang S, Fu Z, Saba NF, Luo M and Teng Y: SMAC-armed oncolytic virotherapy enhances the anticancer activity of PD1 blockade by modulating PANoptosis. Biomark Res. 13:82025. View Article : Google Scholar : PubMed/NCBI

Chen WY, Chen YL, Lin HW, Chang CF, Huang BS, Sun WZ and Cheng WF: Stereotactic body radiation combined with oncolytic vaccinia virus induces potent anti-tumor effect by triggering tumor cell necroptosis and DAMPs. Cancer Lett. 523:149–161. 2021. View Article : Google Scholar : PubMed/NCBI

Cui B, Song L, Wang Q, Li K, He Q, Wu X, Gao F, Liu M, An C, Gao Q, et al: Non-small cell lung cancers (NSCLCs) oncolysis using coxsackievirus B5 and synergistic DNA-damage response inhibitors. Signal Transduct Target Ther. 8:3662023. View Article : Google Scholar : PubMed/NCBI

Ding J, Su R, Yang R, Xu J, Liu X, Yao T, Li S, Wang C, Zhang H, Yue Q, et al: Enhancing the antitumor efficacy of oncolytic adenovirus through sonodynamic therapy-augmented virus replication. ACS Nano. 18:18282–18298. 2024. View Article : Google Scholar : PubMed/NCBI

Kan X, Yin Y, Song C, Tan L, Qiu X, Liao Y, Liu W, Meng S, Sun Y and Ding C: Newcastle-disease-virus-induced ferroptosis through nutrient deprivation and ferritinophagy in tumor cells. iScience. 24:1028372021. View Article : Google Scholar : PubMed/NCBI

Koks CA, Garg AD, Ehrhardt M, Riva M, Vandenberk L, Boon L, De Vleeschouwer S, Agostinis P, Graf N and Van Gool SW: Newcastle disease virotherapy induces long-term survival and tumor-specific immune memory in orthotopic glioma through the induction of immunogenic cell death. Int J Cancer. 136:E313–E325. 2015. View Article : Google Scholar

Li W, Ji T, Ye J, Xiong S, Si Y, Sun X, Li F and Dai Z: Ferroptosis enhances the therapeutic potential of oncolytic adenoviruses KD01 against cancer. Cancer Gene Ther. 32:403–417. 2025. View Article : Google Scholar : PubMed/NCBI

Liu W, Chen H, Zhu Z, Liu Z, Ma C, Lee YJ, Bartlett DL and Guo ZS: Ferroptosis inducer improves the efficacy of oncolytic virus-mediated cancer immunotherapy. Biomedicines. 10:14252022. View Article : Google Scholar : PubMed/NCBI

Rozilah MI, Yusoff K, Chia SL and Ismail S: Autophagy inhibition suppresses Newcastle disease virus-induced cell death by inhibiting viral replication in human breast cancer cells. Virology. 590:1099572024. View Article : Google Scholar

Su W, Qiu W, Li SJ, Wang S, Xie J, Yang QC, Xu J, Zhang J, Xu Z and Sun ZJ: A dual-responsive STAT3 inhibitor nanoprodrug combined with oncolytic virus elicits synergistic antitumor immune responses by igniting pyroptosis. Adv Mater. 35:e22093792023. View Article : Google Scholar

Sun Y, Tang L, Kan X, Tan L, Song C, Qiu X, Liao Y, Nair V, Ding C, Liu X and Sun Y: Oncolytic Newcastle disease virus induced degradation of YAP through E3 ubiquitin ligase PRKN to exacerbate ferroptosis in tumor cells. J Virol. 98:e01897232024. View Article : Google Scholar : PubMed/NCBI

Tamura S, Tazawa H, Hori N, Li Y, Yamada M, Kikuchi S, Kuroda S, Urata Y, Kagawa S and Fujiwara T: p53-armed oncolytic adenovirus induces autophagy and apoptosis in KRAS and BRAF-mutant colorectal cancer cells. PLoS One. 18:e02944912023. View Article : Google Scholar : PubMed/NCBI

Wang ZM, Li MK, Yang QL, Duan SX, Lou XY, Yang XY, Liu Y, Zhong YW, Qiao Y, Wang ZS, et al: Recombinant human adenovirus type 5 promotes anti-tumor immunity via inducing pyroptosis in tumor endothelial cells. Acta Pharmacol Sin. 45:2646–2656. 2024. View Article : Google Scholar : PubMed/NCBI

Zhang CD, Wang YL, Zhou DM, Zhu MY, Lv Y, Hao XQ, Qu CF, Chen Y, Gu WZ, Wu BQ, et al: A recombinant Chinese measles virus vaccine strain rMV-Hu191 inhibits human colorectal cancer growth through inducing autophagy and apoptosis regulating by PI3K/AKT pathway. Transl Oncol. 14:1010912021. View Article : Google Scholar : PubMed/NCBI

Zhang Y, Xu T, Tian H, Wu J, Yu X, Zeng L, Liu F, Liu Q and Huang X: Coxsackievirus group B3 has oncolytic activity against colon cancer through gasdermin E-mediated pyroptosis. Cancers (Basel). 14:62062022. View Article : Google Scholar : PubMed/NCBI

Crow YJ and Casanova JL: Human life within a narrow range: The lethal ups and downs of type I interferons. Sci Immunol. 9:eadm81852024. View Article : Google Scholar : PubMed/NCBI

Mesev EV, LeDesma RA and Ploss A: Decoding type I and III interferon signalling during viral infection. Nat Microbiol. 4:914–924. 2019. View Article : Google Scholar : PubMed/NCBI

Guo YY, Gao Y, Zhao YL, Xie C, Gan H, Cheng X, Yang LP, Hu J, Shu HB, Zhong B, et al: Viral infection and spread are inhibited by the polyubiquitination and downregulation of TRPV2 channel by the interferon-stimulated gene TRIM21. Cell Rep. 43:1140952024. View Article : Google Scholar : PubMed/NCBI

Guo YY, Gao Y, Hu YR, Zhao Y, Jiang D, Wang Y, Zhang Y, Gan H, Xie C, Liu Z, et al: The transient receptor potential vanilloid 2 (TRPV2) channel facilitates virus infection through the Ca(2+) -LRMDA axis in myeloid cells. Adv Sci (Weinh). 9:e22028572022. View Article : Google Scholar : PubMed/NCBI

Ebrahimi S, Ghorbani E, Khazaei M, Avan A, Ryzhikov M, Azadmanesh K and Hassanian SM: Interferon-mediated tumor resistance to oncolytic virotherapy. J Cell Biochem. 118:1994–1999. 2017. View Article : Google Scholar : PubMed/NCBI

Michalska A, Blaszczyk K, Wesoly J and Bluyssen HAR: A positive feedback amplifier circuit that regulates interferon (IFN)-stimulated gene expression and controls type I and II IFN responses. Front Immunol. 9:11352018. View Article : Google Scholar

Sobol PT, Hummel JL, Rodrigues RM and Mossman KL: PML has a predictive role in tumor cell permissiveness to interferon-sensitive oncolytic viruses. Gene Ther. 16:1077–1087. 2009. View Article : Google Scholar : PubMed/NCBI

Sun B, Sundström KB, Chew JJ, Bist P, Gan ES, Tan HC, Goh KC, Chawla T, Tang CK and Ooi EE: Dengue virus activates cGAS through the release of mitochondrial DNA. Sci Rep. 7:35942017. View Article : Google Scholar : PubMed/NCBI

Aguirre S, Luthra P, Sanchez-Aparicio MT, Maestre AM, Patel J, Lamothe F, Fredericks AC, Tripathi S, Zhu T, Pintado-Silva J, et al: Dengue virus NS2B protein targets cGAS for degradation and prevents mitochondrial DNA sensing during infection. Nat Microbiol. 2:170372017. View Article : Google Scholar : PubMed/NCBI

Liikanen I, Monsurrò V, Ahtiainen L, Raki M, Hakkarainen T, Diaconu I, Escutenaire S, Hemminki O, Dias JD, Cerullo V, et al: Induction of interferon pathways mediates in vivo resistance to oncolytic adenovirus. Mol Ther. 19:1858–1866. 2011. View Article : Google Scholar : PubMed/NCBI

Li S, Zhu M, Pan R, Fang T, Cao YY, Chen S, Zhao X, Lei CQ, Guo L, Chen Y, et al: The tumor suppressor PTEN has a critical role in antiviral innate immunity. Nat Immunol. 17:241–249. 2016. View Article : Google Scholar

Pikor LA, Bell JC and Diallo JS: Oncolytic viruses: Exploiting cancer's deal with the devil. Trends Cancer. 1:266–277. 2015. View Article : Google Scholar : PubMed/NCBI

Delaunay T, Achard C, Boisgerault N, Grard M, Petithomme T, Chatelain C, Dutoit S, Blanquart C, Royer PJ, Minvielle S, et al: Frequent homozygous deletions of type I interferon genes in pleural mesothelioma confer sensitivity to oncolytic measles virus. J Thorac Oncol. 15:827–842. 2020. View Article : Google Scholar : PubMed/NCBI

Lipatova AV, Soboleva AV, Gorshkov VA, Bubis JA, Solovyeva EM, Krasnov GS, Kochetkov DV, Vorobyev PO, Ilina IY, Moshkovskii SA, et al: Multi-omics analysis of glioblastoma cells' sensitivity to oncolytic viruses. Cancers (Basel). 13:52682021. View Article : Google Scholar : PubMed/NCBI

Speer SD, Li Z, Buta S, Payelle-Brogard B, Qian L, Vigant F, Rubino E, Gardner TJ, Wedeking T, Hermann M, et al: ISG15 deficiency and increased viral resistance in humans but not mice. Nat Commun. 7:114962016. View Article : Google Scholar : PubMed/NCBI

Friedman GK, Bernstock JD, Chen D, Nan L, Moore BP, Kelly VM, Youngblood SL, Langford CP, Han X, Ring EK, et al: Enhanced sensitivity of patient-derived pediatric high-grade brain tumor xenografts to oncolytic HSV-1 virotherapy correlates with nectin-1 expression. Sci Rep. 8:139302018. View Article : Google Scholar : PubMed/NCBI

Song D, Jia X, Liu X, Hu L, Lin K, Xiao T, Qiao Y, Zhang J, Dan J, Wong C, et al: Identification of the receptor of oncolytic virus M1 as a therapeutic predictor for multiple solid tumors. Signal Transduct Target Ther. 7:1002022. View Article : Google Scholar : PubMed/NCBI

Höti N, Johnson TJ, Chowdhury WH and Rodriguez R: Loss of cyclin-dependent kinase inhibitor alters oncolytic adenovirus replication and promotes more efficient virus production. Cancers (Basel). 10:2022018. View Article : Google Scholar : PubMed/NCBI

Matveeva OV and Chumakov PM: Defects in interferon pathways as potential biomarkers of sensitivity to oncolytic viruses. Rev Med Virol. 28:e20082018. View Article : Google Scholar : PubMed/NCBI

Kedarinath K, Fox CR, Crowgey E, Mazar J, Phelan P, Westmoreland TJ, Alexander KA and Parks GD: CD24 Expression dampens the basal antiviral state in human neuroblastoma cells and enhances permissivity to zika virus infection. Viruses. 14:17352022. View Article : Google Scholar : PubMed/NCBI

Chen X, Liu J, Li Y, Zeng Y, Wang F, Cheng Z, Duan H, Pan G, Yang S, Chen Y, et al: IDH1 mutation impairs antiviral response and potentiates oncolytic virotherapy in glioma. Nat Commun. 14:67812023. View Article : Google Scholar : PubMed/NCBI

Stavrakaki E, Dirven CMF and Lamfers MLM: Personalizing oncolytic virotherapy for glioblastoma: In search of biomarkers for response. Cancers (Basel). 13:6142021. View Article : Google Scholar : PubMed/NCBI

Vasilevska J, De Souza GA, Stensland M, Skrastina D, Zhulenvovs D, Paplausks R, Kurena B, Kozlovska T and Zajakina A: Comparative protein profiling of B16 mouse melanoma cells susceptible and non-susceptible to alphavirus infection: Effect of the tumor microenvironment. Cancer Biol Ther. 17:1035–1050. 2016. View Article : Google Scholar : PubMed/NCBI

Qian ZY, Pan YQ, Li XX, Chen YX, Wu HX, Liu ZX, Kosar M, Bartek J, Wang ZX and Xu RH: Modulator of TMB-associated immune infiltration (MOTIF) predicts immunotherapy response and guides combination therapy. Sci Bull (Beijing). 69:803–822. 2024. View Article : Google Scholar : PubMed/NCBI

Cheng Y, Bu D, Zhang Q, Sun R, Lyle S, Zhao G, Dong L, Li H, Zhao Y, Yu J and Hao X: Genomic and transcriptomic profiling indicates the prognosis significance of mutational signature for TMB-high subtype in Chinese patients with gastric cancer. J Adv Res. 51:121–134. 2023. View Article : Google Scholar :

Wilbur HC, Le DT and Agarwal P: Immunotherapy of MSI cancer: Facts and hopes. Clin Cancer Res. 30:1438–1447. 2024. View Article : Google Scholar

Patel AP, Tirosh I, Trombetta JJ, Shalek AK, Gillespie SM, Wakimoto H, Cahill DP, Nahed BV, Curry WT, Martuza RL, et al: Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science. 344:1396–1401. 2014. View Article : Google Scholar : PubMed/NCBI

Bieler A, Mantwill K, Dravits T, Bernshausen A, Glockzin G, Köhler-Vargas N, Lage H, Gansbacher B and Holm PS: Novel three-pronged strategy to enhance cancer cell killing in glioblastoma cell lines: Histone deacetylase inhibitor, chemotherapy, and oncolytic adenovirus dl520. Hum Gene Ther. 17:55–70. 2009. View Article : Google Scholar

Kitazono M, Goldsmith ME, Aikou T, Bates S and Fojo T: Enhanced adenovirus transgene expression in malignant cells treated with the histone deacetylase inhibitor FR901228. Cancer Res. 61:6328–6330. 2001.PubMed/NCBI

Chang HG, Choi YH, Hong J, Choi JW, Yoon AR and Yun CO: GM101 in combination with histone deacetylase inhibitor enhances anti-tumor effects in desmoplastic microenvironment. Cells. 10:28112021. View Article : Google Scholar : PubMed/NCBI

Jaime-Ramirez AC, Yu JG, Caserta E, Yoo JY, Zhang J, Lee TJ, Hofmeister C, Lee JH, Kumar B, Pan Q, et al: Reolysin and histone deacetylase inhibition in the treatment of head and neck squamous cell carcinoma. Mol Ther Oncolytics. 5:87–96. 2017. View Article : Google Scholar : PubMed/NCBI

Tong Y, Zhu W, Huang X, You L, Han X, Yang C and Qian W: PI3K inhibitor LY294002 inhibits activation of the Akt/mTOR pathway induced by an oncolytic adenovirus expressing TRAIL and sensitizes multiple myeloma cells to the oncolytic virus. Oncol Rep. 31:1581–1588. 2014. View Article : Google Scholar : PubMed/NCBI

Wang L, Ning J, Wakimoto H, Wu S, Wu CL, Humphrey MR, Rabkin SD and Martuza RL: Oncolytic herpes simplex virus and PI3K inhibitor BKM120 synergize to promote killing of prostate cancer stem-like cells. Mol Ther Oncolytics. 13:58–66. 2019. View Article : Google Scholar : PubMed/NCBI

Hsu WH, LaBella KA, Lin Y, Xu P, Lee R, Hsieh CE, Yang L, Zhou A, Blecher JM, Wu CJ, et al: Oncogenic KRAS drives lipofibrogenesis to promote angiogenesis and colon cancer progression. Cancer Discov. 13:2652–2673. 2023. View Article : Google Scholar : PubMed/NCBI

Mahller YY, Vaikunth SS, Currier MA, Miller SJ, Ripberger MC, Hsu YH, Mehrian-Shai R, Collins MH, Crombleholme TM, Ratner N and Cripe TP: Oncolytic HSV and erlotinib inhibit tumor growth and angiogenesis in a novel malignant peripheral nerve sheath tumor xenograft model. Mol Ther. 15:279–286. 2007. View Article : Google Scholar : PubMed/NCBI

Wu Z, Ichinose T, Naoe Y, Matsumura S, Villalobos IB, Eissa IR, Yamada S, Miyajima N, Morimoto D, Mukoyama N, et al: Combination of cetuximab and oncolytic virus canerpaturev synergistically inhibits human colorectal cancer growth. Mol Ther Oncolytics. 13:107–115. 2019. View Article : Google Scholar : PubMed/NCBI

Yamamura K, Kasuya H, Sahin TT, Tan G, Hotta Y, Tsurumaru N, Fukuda S, Kanda M, Kobayashi D, Tanaka C, et al: Combination treatment of human pancreatic cancer xenograft models with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib and oncolytic herpes simplex virus HF10. Ann Surg Oncol. 21:691–698. 2014. View Article : Google Scholar

Jha BK, Dong B, Nguyen CT, Polyakova I and Silverman RH: Suppression of antiviral innate immunity by sunitinib enhances oncolytic virotherapy. Mol Ther. 21:1749–1757. 2013. View Article : Google Scholar : PubMed/NCBI

Coffey MC, Strong JE, Forsyth PA and Lee PW: Reovirus therapy of tumors with activated Ras pathway. Science. 282:1332–1334. 1998. View Article : Google Scholar : PubMed/NCBI

Gong J and Mita MM: Activated ras signaling pathways and reovirus oncolysis: An update on the mechanism of preferential reovirus replication in cancer cells. Front Oncol. 4:1672014. View Article : Google Scholar : PubMed/NCBI

Cai J, Lin K, Cai W, Lin Y, Liu X, Guo L, Zhang J, Xu W, Lin Z, Wong CW, et al: Tumors driven by RAS signaling harbor a natural vulnerability to oncolytic virus M1. Mol Oncol. 14:3153–3168. 2020. View Article : Google Scholar : PubMed/NCBI

Zhu Z, McGray AJR, Jiang W, Lu B, Kalinski P and Guo ZS: Improving cancer immunotherapy by rationally combining oncolytic virus with modulators targeting key signaling pathways. Mol Cancer. 21:1962022. View Article : Google Scholar : PubMed/NCBI

Hingorani SR: Epithelial and stromal co-evolution and complicity in pancreatic cancer. Nat Rev Cancer. 23:57–77. 2023. View Article : Google Scholar :

Dalin S, Sullivan MR, Lau AN, Grauman-Boss B, Mueller HS, Kreidl E, Fenoglio S, Luengo A, Lees JA, Vander Heiden MG, et al: Deoxycytidine release from pancreatic stellate cells promotes gemcitabine resistance. Cancer Res. 79:5723–5733. 2019. View Article : Google Scholar : PubMed/NCBI

Fischer A and Alsina-Sanchis E: Disturbed endothelial cell signaling in tumor progression and therapy resistance. Curr Opin Cell Biol. 86:1022872024. View Article : Google Scholar

Sun Y: Tumor microenvironment and cancer therapy resistance. Cancer Lett. 380:205–215. 2016. View Article : Google Scholar

Chen L, Xu YX, Wang YS, Ren YY, Dong XM, Wu P, Xie T, Zhang Q and Zhou JL: Prostate cancer microenvironment: Multidimensional regulation of immune cells, vascular system, stromal cells, and microbiota. Mol Cancer. 23:2292024. View Article : Google Scholar : PubMed/NCBI

Zheng Y, Zhou R, Cai J, Yang N, Wen Z, Zhang Z, Sun H, Huang G, Guan Y, Huang N, et al: Matrix stiffness triggers lipid metabolic cross-talk between tumor and stromal cells to mediate bevacizumab resistance in colorectal cancer liver metastases. Cancer Res. 83:3577–3592. 2023. View Article : Google Scholar : PubMed/NCBI

Cescon M, Rampazzo E, Bresolin S, Da Ros F, Manfreda L, Cani A, Della Puppa A, Braghetta P, Bonaldo P and Persano L: Collagen VI sustains cell stemness and chemotherapy resistance in glioblastoma. Cell Mol Life Sci. 80:2332023. View Article : Google Scholar : PubMed/NCBI

Zhu J, Ma J, Huang M, Deng H and Shi G: Emerging delivery strategy for oncolytic virotherapy. Mol Ther Oncol. 32:2008092024. View Article : Google Scholar : PubMed/NCBI

Guelfi S, Hodivala-Dilke K and Bergers G: Targeting the tumour vasculature: From vessel destruction to promotion. Nat Rev Cancer. 24:655–675. 2024. View Article : Google Scholar : PubMed/NCBI

Wan PK, Ryan AJ and Seymour LW: Beyond cancer cells: Targeting the tumor microenvironment with gene therapy and armed oncolytic virus. Mol Ther. 29:1668–1682. 2021. View Article : Google Scholar : PubMed/NCBI

Miller A, Nace R, Ayala-Breton CC, Steele M, Bailey K, Peng KW and Russell SJ: Perfusion pressure is a critical determinant of the intratumoral extravasation of oncolytic viruses. Mol Ther. 24:306–317. 2016. View Article : Google Scholar :

Hong B, Muili K, Bolyard C, Russell L, Lee TJ, Banasavadi-Siddegowda Y, Yoo JY, Yan Y, Ballester LY, Bockhorst KH and Kaur B: Suppression of HMGB1 released in the glioblastoma tumor microenvironment reduces tumoral edema. Mol Ther Oncolytics. 12:93–102. 2018. View Article : Google Scholar

Tseng JC, Granot T, DiGiacomo V, Levin B and Meruelo D: Enhanced specific delivery and targeting of oncolytic Sindbis viral vectors by modulating vascular leakiness in tumor. Cancer Gene Ther. 17:244–255. 2010. View Article : Google Scholar :

Kurozumi K, Hardcastle J, Thakur R, Yang M, Christoforidis G, Fulci G, Hochberg FH, Weissleder R, Carson W, Chiocca EA and Kaur B: Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy. J Natl Cancer Inst. 99:1768–1781. 2007. View Article : Google Scholar : PubMed/NCBI

Liu ZL, Chen HH, Zheng LL, Sun LP and Shi L: Angiogenic signaling pathways and anti-angiogenic therapy for cancer. Signal Transduct Target Ther. 8:1982023. View Article : Google Scholar : PubMed/NCBI

Yousaf I, Kaeppler J, Frost S, Seymour LW and Jacobus EJ: Attenuation of the Hypoxia inducible factor pathway after oncolytic adenovirus infection coincides with decreased vessel perfusion. Cancers (Basel). 12:8512020. View Article : Google Scholar : PubMed/NCBI

Breitbach CJ, De Silva NS, Falls TJ, Aladl U, Evgin L, Paterson J, Sun YY, Roy DG, Rintoul JL, Daneshmand M, et al: Targeting tumor vasculature with an oncolytic virus. Mol Ther. 19:886–894. 2011. View Article : Google Scholar : PubMed/NCBI

Kim M, Nitschké M, Sennino B, Murer P, Schriver BJ, Bell A, Subramanian A, McDonald CE, Wang J, Cha H, et al: Amplification of oncolytic vaccinia virus widespread tumor cell killing by sunitinib through multiple mechanisms. Cancer Res. 78:922–937. 2018. View Article : Google Scholar

Hou W, Chen H, Rojas J, Sampath P and Thorne SH: Oncolytic vaccinia virus demonstrates antiangiogenic effects mediated by targeting of VEGF. Int J Cancer. 135:1238–1246. 2014. View Article : Google Scholar : PubMed/NCBI

Rizzo R, D'Accolti M, Bortolotti D, Caccuri F, Caruso A, Di Luca D and Caselli E: Human Herpesvirus 6A and 6B inhibit in vitro angiogenesis by induction of Human Leukocyte Antigen G. Sci Rep. 8:176832018. View Article : Google Scholar : PubMed/NCBI

Naumenko VA, Stepanenko AA, Lipatova AV, Vishnevskiy DA and Chekhonin VP: Infection of non-cancer cells: A barrier or support for oncolytic virotherapy? Mol Ther Oncolytics. 24:663–682. 2022. View Article : Google Scholar : PubMed/NCBI

Nair M, Khosla M, Otani Y, Yeh M, Park F, Shimizu T, Kang JM, Bolyard C, Yu JG, Kumar Banasavadi-Siddegowda Y, et al: Enhancing antitumor efficacy of heavily vascularized tumors by RAMBO virus through decreased tumor endothelial cell activation. Cancers (Basel). 12:10402020. View Article : Google Scholar : PubMed/NCBI

Aghi M, Rabkin SD and Martuza RL: Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide. Cancer Res. 67:440–444. 2007. View Article : Google Scholar : PubMed/NCBI

Kurozumi K, Hardcastle J, Thakur R, Shroll J, Nowicki M, Otsuki A, Chiocca EA and Kaur B: Oncolytic HSV-1 infection of tumors induces angiogenesis and upregulates CYR61. Mol Ther. 16:1382–1391. 2008. View Article : Google Scholar : PubMed/NCBI

Hassan M, Selimovic D, El-Khattouti A, Soell M, Ghozlan H, Haikel Y, Abdelkader O and Megahed M: Hepatitis C virus-mediated angiogenesis: Molecular mechanisms and therapeutic strategies. World J Gastroenterol. 20:15467–15475. 2014. View Article : Google Scholar : PubMed/NCBI

Wigner-Jeziorska P, Janik-Karpińska E, Niwald M, Saluk J and Miller E: Effect of SARS-CoV-2 infection and BNT162b2 vaccination on the mRNA expression of genes associated with angiogenesis. Int J Mol Sci. 24:160942023. View Article : Google Scholar : PubMed/NCBI

Arulanandam R, Batenchuk C, Angarita FA, Ottolino-Perry K, Cousineau S, Mottashed A, Burgess E, Falls TJ, De Silva N, Tsang J, et al: VEGF-mediated induction of PRD1-BF1/Blimp1 expression sensitizes tumor vasculature to oncolytic virus infection. Cancer Cell. 28:210–224. 2015. View Article : Google Scholar : PubMed/NCBI

Cords L, Engler S, Haberecker M, Rüschoff JH, Moch H, de Souza N and Bodenmiller B: Cancer-associated fibroblast phenotypes are associated with patient outcome in non-small cell lung cancer. Cancer Cell. 42:396–412.e5. 2024. View Article : Google Scholar : PubMed/NCBI

Wang H, Li N, Liu Q, Guo J, Pan Q, Cheng B, Xu J, Dong B, Yang G, Yang B, et al: Antiandrogen treatment induces stromal cell reprogramming to promote castration resistance in prostate cancer. Cancer Cell. 41:1345–1362.e9. 2023. View Article : Google Scholar : PubMed/NCBI

Qi R, Bai Y, Li K, Liu N, Xu Y, Dal E, Wang Y, Lin R, Wang H, Liu Z, et al: Cancer-associated fibroblasts suppress ferroptosis and induce gemcitabine resistance in pancreatic cancer cells by secreting exosome-derived ACSL4-targeting miRNAs. Drug Resist Updat. 68:1009602023. View Article : Google Scholar : PubMed/NCBI

Vähä-Koskela MJ, Kallio JP, Jansson LC, Heikkilä JE, Zakhartchenko VA, Kallajoki MA, Kähäri VM and Hinkkanen AE: Oncolytic capacity of attenuated replicative semliki forest virus in human melanoma xenografts in severe combined immunodeficient mice. Cancer Res. 66:7185–7194. 2066. View Article : Google Scholar

Arwert EN, Milford EL, Rullan A, Derzsi S, Hooper S, Kato T, Mansfield D, Melcher A, Harrington KJ and Sahai E: STING and IRF3 in stromal fibroblasts enable sensing of genomic stress in cancer cells to undermine oncolytic viral therapy. Nat Cell Biol. 22:758–766. 2020. View Article : Google Scholar : PubMed/NCBI

Yasui T, Ohuchida K, Zhao M, Onimaru M, Egami T, Fujita H, Ohtsuka T, Mizumoto K and Tanaka M: Tumor-stroma interactions reduce the efficacy of adenoviral therapy through the HGF-MET pathway. Cancer Sci. 102:484–491. 2011. View Article : Google Scholar

van Asten SD, Raaben M, Nota B and Spaapen RM: Secretome screening reveals fibroblast growth factors as novel inhibitors of viral replication. J Virol. 92:e00260–18. 2018. View Article : Google Scholar : PubMed/NCBI

Hiller BE, Yin Y, Perng YC, de Araujo Castro Í, Fox LE, Locke MC, Monte KJ, López CB, Ornitz DM and Lenschow DJ: Fibroblast growth factor-9 expression in airway epithelial cells amplifies the type I interferon response and alters influenza A virus pathogenesis. PLoS Pathog. 18:e10102282022. View Article : Google Scholar : PubMed/NCBI

Maddaluno L, Urwyler C, Rauschendorfer T, Meyer M, Stefanova D, Spörri R, Wietecha M, Ferrarese L, Stoycheva D, Bender D, et al: Antagonism of interferon signaling by fibroblast growth factors promotes viral replication. EMBO Mol Med. 12:e117932020. View Article : Google Scholar : PubMed/NCBI

Puig-Saus C, Gros A, Alemany R and Cascalló M: Adenovirus i-leader truncation bioselected against cancer-associated fibroblasts to overcome tumor stromal barriers. Mol Ther. 20:54–62. 2012. View Article : Google Scholar :

Kurisu N, Kaminade T, Eguchi M, Ishigami I, Mizuguchi H and Sakurai F: Oncolytic reovirus-mediated killing of mouse cancer-associated fibroblasts. Int J Pharm. 610:1212692021. View Article : Google Scholar : PubMed/NCBI

de Sostoa J, Fajardo CA, Moreno R, Ramos MD, Farrera-Sal M and Alemany R: Targeting the tumor stroma with an oncolytic adenovirus secreting a fibroblast activation protein-targeted bispecific T-cell engager. J Immunother Cancer. 7:192019. View Article : Google Scholar : PubMed/NCBI

Harryvan TJ, Golo M, Dam N, Schoonderwoerd MJA, Farshadi EA, Hornsveld M, Hoeben RC, Hawinkels LJAC and Kemp V: Gastrointestinal cancer-associated fibroblasts expressing Junctional Adhesion Molecule-A are amenable to infection by oncolytic reovirus. Cancer Gene Ther. 29:1918–1929. 2022. View Article : Google Scholar : PubMed/NCBI

Jing Y, Chavez V, Ban Y, Acquavella N, El-Ashry D, Pronin A, Chen X and Merchan JR: Molecular effects of stromal-selective targeting by uPAR-retargeted oncolytic virus in breast cancer. Mol Cancer Res. 15:1410–1420. 2017. View Article : Google Scholar : PubMed/NCBI

Shahvali S, Rahiman N, Jaafari MR and Arabi L: Targeting fibroblast activation protein (FAP): Advances in CAR-T cell, antibody, and vaccine in cancer immunotherapy. Drug Deliv Transl Res. 13:2041–2056. 2023. View Article : Google Scholar : PubMed/NCBI

Al-Obaidi I, Sandhu C, Qureshi B and Seymour LW: The implications of oncolytic viruses targeting fibroblasts in enhancing the antitumoural immune response. Heliyon. 10:e392042024. View Article : Google Scholar : PubMed/NCBI

Chen X and Song E: Turning foes to friends: Targeting cancer-associated fibroblasts. Nat Rev Drug Discov. 18:99–115. 2019. View Article : Google Scholar

Long F, Zhong W, Zhao F, Xu Y, Hu X, Jia G, Huang L, Yi K, Wang N, Si H, et al: DAB2 (+) macrophages support FAP (+) fibroblasts in shaping tumor barrier and inducing poor clinical outcomes in liver cancer. Theranostics. 14:4822–4843. 2024. View Article : Google Scholar : PubMed/NCBI

Yashaswini CN, Qin T, Bhattacharya D, Amor C, Lowe S, Lujambio A, Wang S and Friedman SL: Phenotypes and ontogeny of senescent hepatic stellate cells in metabolic dysfunction-associated steatohepatitis. J Hepatol. 81:207–217. 2024. View Article : Google Scholar : PubMed/NCBI

Yang T, Zhai J, Hu D, Yang R, Wang G, Li Y and Liang G: 'Targeting Design' of nanoparticles in tumor therapy. Pharmaceutics. 14:19192022. View Article : Google Scholar

Guedan S, Rojas JJ, Gros A, Mercade E, Cascallo M and Alemany R: Hyaluronidase expression by an oncolytic adenovirus enhances its intratumoral spread and suppresses tumor growth. Mol Ther. 18:1275–1283. 2010. View Article : Google Scholar : PubMed/NCBI

Fang L, Kong SS, Zhong LK, Wang CM, Liu YJ, Ding HY, Sun J, Zhang YW, Li FZ and Huang P: Asiatic acid enhances intratumor delivery and the antitumor effect of pegylated liposomal doxorubicin by reducing tumor-stroma collagen. Acta Pharmacol Sin. 40:539–545. 2019. View Article : Google Scholar :

Haseley A, Boone S, Wojton J, Yu L, Yoo JY, Yu J, Kurozumi K, Glorioso JC, Caligiuri MA and Kaur B: Extracellular matrix protein CCN1 limits oncolytic efficacy in glioma. Cancer Res. 72:1353–1362. 2012. View Article : Google Scholar : PubMed/NCBI

Maillard L, Ziol M, Tahlil O, Le Feuvre C, Feldman LJ, Branellec D, Bruneval P and Steg P: Pre-treatment with elastase improves the efficiency of percutaneous adenovirus-mediated gene transfer to the arterial media. Gene Ther. 5:1023–1030. 1998. View Article : Google Scholar

Kuriyama N, Kuriyama H, Julin CM, Lamborn KR and Israel MA: Protease pretreatment increases the efficacy of adenovirus-mediated gene therapy for the treatment of an experimental glioblastoma model. Cancer Res. 61:1805–1809. 2001.PubMed/NCBI

Kuriyama N, Kuriyama H, Julin CM, Lamborn K and Israel MA: Pretreatment with protease is a useful experimental strategy for enhancing adenovirus-mediated cancer gene therapy. Hum Gene Ther. 11:2219–2230. 2000. View Article : Google Scholar : PubMed/NCBI

McKee TD, Grandi P, Mok W, Alexandrakis G, Insin N, Zimmer JP, Bawendi MG, Boucher Y, Breakefield XO and Jain RK: Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector. Cancer Res. 66:2509–2513. 2006. View Article : Google Scholar : PubMed/NCBI

Bhattacharyya M, Jariyal H and Srivastava A: Hyaluronic acid: More than a carrier, having an overpowering extracellular and intracellular impact on cancer. Carbohydr Polym. 317:1210812023. View Article : Google Scholar : PubMed/NCBI

Ganesh S, Gonzalez-Edick M, Gibbons D, Van Roey M and Jooss K: Intratumoral coadministration of hyaluronidase enzyme and oncolytic adenoviruses enhances virus potency in metastatic tumor models. Clin Cancer Res. 14:3933–3941. 2008. View Article : Google Scholar : PubMed/NCBI

Samuel CS, Hewitson TD, Unemori EN and Tang ML: Drugs of the future: the hormone relaxin. Cell Mol Life Sci. 64:1539–1557. 2007. View Article : Google Scholar : PubMed/NCBI

Perentes JY, McKee TD, Ley CD, Mathiew H, Dawson M, Padera TP, Munn LL, Jain RK and Boucher Y: In vivo imaging of extracellular matrix remodeling by tumor-associated fibroblasts. Nat Methods. 6:143–145. 2009. View Article : Google Scholar : PubMed/NCBI

Kim JH, Lee YS, Kim H, Huang JH, Yoon AR and Yun CO: Relaxin expression from tumor-targeting adenoviruses and its intratumoral spread, apoptosis induction, and efficacy. J Natl Cancer Inst. 98:1482–1493. 2006. View Article : Google Scholar : PubMed/NCBI

Kim Y, Lee HG, Dmitrieva N, Kim J, Kaur B and Friedman A: Choindroitinase ABC I-mediated enhancement of oncolytic virus spread and anti tumor efficacy: A mathematical model. PLoS One. 9:e1024992014. View Article : Google Scholar : PubMed/NCBI

Mok W, Boucher Y and Jain RK: Matrix metalloproteinases-1 and -8 improve the distribution and efficacy of an oncolytic virus. Cancer Res. 67:10664–10668. 2007. View Article : Google Scholar : PubMed/NCBI

Hong CS, Fellows W, Niranjan A, Alber S, Watkins S, Cohen JB, Glorioso JC and Grandi P: Ectopic matrix metalloproteinase-9 expression in human brain tumor cells enhances oncolytic HSV vector infection. Gene Ther. 17:1200–1205. 2010. View Article : Google Scholar : PubMed/NCBI

Yumul R, Richter M, Lu ZZ, Saydaminova K, Wang H, Wang CH, Carter D and Lieber A: Epithelial junction opener improves oncolytic adenovirus therapy in mouse tumor models. Hum Gene Ther. 27:325–337. 2016. View Article : Google Scholar : PubMed/NCBI

Binder C, Simon A, Binder L, Hagemann T, Schulz M, Emons G, Trümper L and Einspanier A: Elevated concentrations of serum relaxin are associated with metastatic disease in breast cancer patients. Breast Cancer Res Treat. 87:157–166. 2004. View Article : Google Scholar : PubMed/NCBI

Daginakatte GC and Gutmann DH: Neurofibromatosis-1 (Nf1) heterozygous brain microglia elaborate paracrine factors that promote Nf1-deficient astrocyte and glioma growth. Hum Mol Genet. 16:1098–1112. 2007. View Article : Google Scholar : PubMed/NCBI

Dmitrieva N, Yu L, Viapiano M, Cripe TP, Chiocca EA, Glorioso JC and Kaur B: Chondroitinase ABC I-mediated enhancement of oncolytic virus spread and antitumor efficacy. Clin Cancer Res. 17:1362–1372. 2011. View Article : Google Scholar

Kanzaki A, Kasuya H, Yamamura K, Sahin TT, Nomura N, Shikano T, Shirota T, Tan G, Fukuda S, Misawa M, et al: Antitumor efficacy of oncolytic herpes simplex virus adsorbed onto antigen-specific lymphocytes. Cancer Gene Ther. 19:292–298. 2012. View Article : Google Scholar : PubMed/NCBI

Netti PA, Berk DA, Swartz MA, Grodzinsky AJ and Jain RK: Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res. 60:2497–2503. 2000.PubMed/NCBI

Yokoda R, Nagalo BM, Vernon B, Oklu R, Albadawi H, DeLeon TT, Zhou Y, Egan JB, Duda DG and Borad MJ: Oncolytic virus delivery: From nano-pharmacodynamics to enhanced oncolytic effect. Oncolytic Virother. 6:39–49. 2017. View Article : Google Scholar : PubMed/NCBI

Kwan A, Winder N and Muthana M: Oncolytic virotherapy treatment of breast cancer: Barriers and recent advances. Viruses. 13:11282021. View Article : Google Scholar : PubMed/NCBI

Fisher KD, Stallwood Y, Green NK, Ulbrich K, Mautner V and Seymour LW: Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies. Gene Ther. 8:341–348. 2001. View Article : Google Scholar : PubMed/NCBI

Wang J, Guo C, Wang XY and Yang H: 'Double-punch' strategy for delivery of viral immunotherapy with prolonged tumor retention and enhanced transfection efficacy. J Control Release. 329:328–336. 2021. View Article : Google Scholar

Thambi T, Hong J, Yoon AR and Yun CO: Challenges and progress toward tumor-targeted therapy by systemic delivery of polymer-complexed oncolytic adenoviruses. Cancer Gene Ther. 29:1321–1331. 2022. View Article : Google Scholar : PubMed/NCBI

Kim J, Kim PH, Kim SW and Yun CO: Enhancing the therapeutic efficacy of adenovirus in combination with biomaterials. Biomaterials. 33:1838–1850. 2012. View Article : Google Scholar

Howard F and Muthana M: Designer nanocarriers for navigating the systemic delivery of oncolytic viruses. Nanomedicine (Lond). 15:93–110. 2020. View Article : Google Scholar

Almstätter I, Mykhaylyk O, Settles M, Altomonte J, Aichler M, Walch A, Rummeny EJ, Ebert O, Plank C and Braren R: Characterization of magnetic viral complexes for targeted delivery in oncology. Theranostics. 5:667–685. 2015. View Article : Google Scholar : PubMed/NCBI

Lara HH, Ayala-Nuñez NV, Ixtepan-Turrent L and Rodriguez-Padilla C: Mode of antiviral action of silver nanoparticles against HIV-1. J Nanobiotechnology. 8:12010. View Article : Google Scholar : PubMed/NCBI

Ran L, Tan X, Li Y, Zhang H, Ma R, Ji T, Dong W, Tong T, Liu Y, Chen D, et al: Delivery of oncolytic adenovirus into the nucleus of tumorigenic cells by tumor microparticles for virotherapy. Biomaterials. 89:56–66. 2016. View Article : Google Scholar : PubMed/NCBI

Hong Y, Kim YK, Kim GB, Nam GH, Kim SA, Park Y, Yang Y and Kim IS: Degradation of tumour stromal hyaluronan by small extracellular vesicle-PH20 stimulates CD103(+) dendritic cells and in combination with PD-L1 blockade boosts anti-tumour immunity. J Extracell Vesicles. 8:16708932019. View Article : Google Scholar : PubMed/NCBI

Liu L, Liu W, Han Z, Shan Y, Xie Y, Wang J, Qi H and Xu Q: Extracellular Vesicles-in-Hydrogel (EViH) targeting pathophysiology for tissue repair. Bioact Mater. 44:283–318. 2024.PubMed/NCBI

Jung BK, Ko HY, Kang H, Hong J, Ahn HM, Na Y, Kim H, Kim JS and Yun CO: Relaxin-expressing oncolytic adenovirus induces remodeling of physical and immunological aspects of cold tumor to potentiate PD-1 blockade. J Immunother Cancer. 8:e0007632020. View Article : Google Scholar : PubMed/NCBI

Wang S, Li Y, Xu C, Dong J and Wei J: An oncolytic vaccinia virus encoding hyaluronidase reshapes the extracellular matrix to enhance cancer chemotherapy and immunotherapy. J Immunother Cancer. 12:e0084312024. View Article : Google Scholar : PubMed/NCBI

Farrera-Sal M, Moreno R, Mato-Berciano A, Maliandi MV, Bazan-Peregrino M and Alemany R: Hyaluronidase expression within tumors increases virotherapy efficacy and T cell accumulation. Mol Ther Oncolytics. 22:27–35. 2021. View Article : Google Scholar : PubMed/NCBI

Schäfer S, Weibel S, Donat U, Zhang Q, Aguilar RJ, Chen NG and Szalay AA: Vaccinia virus-mediated intra-tumoral expression of matrix metalloproteinase 9 enhances oncolysis of PC-3 xenograft tumors. BMC Cancer. 12:3662012. View Article : Google Scholar : PubMed/NCBI

Swanner J, Shim JS, Rivera-Caraballo KA, Vázquez-Arreguín K, Hong B, Bueso-Perez AJ, Lee TJ, Banasavadi-Siddegowda YK, Kaur B and Yoo JY: esRAGE-expressing oHSV enhances anti-tumor efficacy by inhibition of endothelial cell activation. Mol Ther Oncolytics. 28:171–181. 2023. View Article : Google Scholar : PubMed/NCBI

Jeong SN and Yoo SY: Novel oncolytic virus armed with cancer suicide gene and normal vasculogenic gene for improved anti-tumor activity. Cancers (Basel). 12:10702020. View Article : Google Scholar : PubMed/NCBI

Al-Zaher AA, Moreno R, Fajardo CA, Arias-Badia M, Farrera M, de Sostoa J, Rojas LA and Alemany R: Evidence of anti-tumoral efficacy in an immune competent setting with an iRGD-Modified hyaluronidase-armed oncolytic adenovirus. Mol Ther Oncolytics. 8:62–70. 2018. View Article : Google Scholar : PubMed/NCBI

Puig-Saus C, Rojas LA, Laborda E, Figueras A, Alba R, Fillat C and Alemany R: iRGD tumor-penetrating peptide-modified oncolytic adenovirus shows enhanced tumor transduction, intratumoral dissemination and antitumor efficacy. Gene Ther. 21:767–774. 2014. View Article : Google Scholar : PubMed/NCBI

Everts A, Bergeman M, McFadden G and Kemp V: Simultaneous tumor and stroma targeting by oncolytic viruses. Biomedicines. 8:4742020. View Article : Google Scholar : PubMed/NCBI

Lavilla-Alonso S, Bauer MM, Abo-Ramadan U, Ristimäki A, Halavaara J, Desmond RA, Wang D, Escutenaire S, Ahtiainen L, Saksela K, et al: Macrophage metalloelastase (MME) as adjuvant for intra-tumoral injection of oncolytic adenovirus and its influence on metastases development. Cancer Gene Ther. 19:126–134. 2012. View Article : Google Scholar

Hu J, Chen C, Lu R, Zhang Y, Wang Y, Hu Q, Li W, Wang S, Jing O, Yi H, et al: β-adrenergic receptor inhibitor and oncolytic herpesvirus combination therapy shows enhanced antitumoral and antiangiogenic effects on colorectal cancer. Front Pharmacol. 12:7352782021. View Article : Google Scholar

Thaci B, Ulasov IV, Ahmed AU, Ferguson SD, Han Y and Lesniak MS: Anti-angiogenic therapy increases intratumoral adenovirus distribution by inducing collagen degradation. Gene Ther. 20:318–327. 2013. View Article : Google Scholar

Ikeda K, Ichikawa T, Wakimoto H, Silver JS, Deisboeck TS, Finkelstein D, Harsh GR IV, Louis DN, Bartus RT, Hochberg FH and Chiocca EA: Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat Med. 5:881–887. 1999. View Article : Google Scholar : PubMed/NCBI

Ikeda K, Wakimoto H, Ichikawa T, Jhung S, Hochberg FH, Louis DN and Chiocca EA: Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant. J Virol. 74:4765–4775. 2000. View Article : Google Scholar : PubMed/NCBI

Carlisle R, Choi J, Bazan-Peregrino M, Laga R, Subr V, Kostka L, Ulbrich K, Coussios CC and Seymour LW: Enhanced tumor uptake and penetration of virotherapy using polymer stealthing and focused ultrasound. J Natl Cancer Inst. 105:1701–1710. 2013. View Article : Google Scholar : PubMed/NCBI

Bazan-Peregrino M, Arvanitis CD, Rifai B, Seymour LW and Coussios CC: Ultrasound-induced cavitation enhances the delivery and therapeutic efficacy of an oncolytic virus in an in vitro model. J Control Release. 157:235–242. 2012. View Article : Google Scholar

Sun S, Liu Y, He C, Hu W, Liu W, Huang X, Wu J, Xie F, Chen C, Wang J, et al: Combining NanoKnife with M1 oncolytic virus enhances anticancer activity in pancreatic cancer. Cancer Lett. 502:9–24. 2021. View Article : Google Scholar : PubMed/NCBI

Otani Y, Yoo JY, Shimizu T, Kurozumi K, Date I and Kaur B: Implications of immune cells in oncolytic herpes simplex virotherapy for glioma. Brain Tumor Pathol. 39:57–64. 2022. View Article : Google Scholar : PubMed/NCBI

Donat U, Weibel S, Hess M, Stritzker J, Härtl B, Sturm JB, Chen NG, Gentschev I and Szalay AA: Preferential colonization of metastases by oncolytic vaccinia virus strain GLV-1h68 in a human PC-3 prostate cancer model in nude mice. PLoS One. 7:e459422012. View Article : Google Scholar : PubMed/NCBI

Lynch C, Pitroda SP and Weichselbaum RR: Radiotherapy, immunity, and immune checkpoint inhibitors. Lancet Oncol. 25:e352–e362. 2024. View Article : Google Scholar : PubMed/NCBI

Munir AZ, Gutierrez A, Qin J, Lichtman AH and Moslehi JJ: Immune-checkpoint inhibitor-mediated myocarditis: CTLA4, PD1 and LAG3 in the heart. Nat Rev Cancer. 24:540–553. 2024. View Article : Google Scholar : PubMed/NCBI

Kwan A, Winder N, Atkinson E, Al-Janabi H, Allen RJ, Hughes R, Moamin M, Louie R, Evans D, Hutchinson M, et al: Macrophages Mediate the Antitumor Effects of the Oncolytic Virus HSV1716 in Mammary Tumors. Mol Cancer Ther. 20:589–601. 2021. View Article : Google Scholar

Bommareddy PK, Aspromonte S, Zloza A, Rabkin SD and Kaufman HL: MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation. Sci Transl Med. 10:eaau04172018. View Article : Google Scholar : PubMed/NCBI

Mostafa AA, Meyers DE, Thirukkumaran CM, Liu PJ, Gratton K, Spurrell J, Shi Q, Thakur S and Morris DG: Oncolytic reovirus and immune checkpoint inhibition as a novel immunotherapeutic strategy for breast cancer. Cancers (Basel). 10:2052018. View Article : Google Scholar : PubMed/NCBI

Burke S, Shergold A, Elder MJ, Whitworth J, Cheng X, Jin H, Wilkinson RW, Harper J and Carroll DK: Oncolytic Newcastle disease virus activation of the innate immune response and priming of antitumor adaptive responses in vitro. Cancer Immunol Immunother. 69:1015–1027. 2020. View Article : Google Scholar : PubMed/NCBI

Chon HJ, Lee WS, Yang H, Kong SJ, Lee NK, Moon ES, Choi J, Han EC, Kim JH, Ahn JB, et al: Tumor microenvironment remodeling by intratumoral oncolytic vaccinia virus enhances the efficacy of immune-checkpoint blockade. Clin Cancer Res. 25:1612–1623. 2019. View Article : Google Scholar

Lovatt C and Parker AL: Oncolytic viruses and immune checkpoint inhibitors: The 'Hot' new power couple. Cancers (Basel). 15:41782023. View Article : Google Scholar

Bernstock JD, Vicario N, Rong L, Valdes PA, Choi BD, Chen JA, DiToro D, Osorio DS, Kachurak K, Gessler F, et al: A novel in situ multiplex immunofluorescence panel for the assessment of tumor immunopathology and response to virotherapy in pediatric glioblastoma reveals a role for checkpoint protein inhibition. Oncoimmunology. 8:e16789212019. View Article : Google Scholar : PubMed/NCBI

Annels NE, Mansfield D, Arif M, Ballesteros-Merino C, Simpson GR, Denyer M, Sandhu SS, Melcher AA, Harrington KJ, Davies B, et al: Phase I Trial of an ICAM-1-targeted immunotherapeutic-coxsackievirus A21 (CVA21) as an oncolytic agent against non muscle-invasive bladder cancer. Clin Cancer Res. 25:5818–5831. 2019. View Article : Google Scholar : PubMed/NCBI

Zhang B, Huang J, Tang J, Hu S, Luo S, Luo Z, Zhou F, Tan S, Ying J, Chang Q, et al: Intratumoral OH2, an oncolytic herpes simplex virus 2, in patients with advanced solid tumors: A multicenter, phase I/II clinical trial. J Immunother Cancer. 9:e0022242021. View Article : Google Scholar : PubMed/NCBI

Saha D, Martuza RL and Rabkin SD: Macrophage polarization contributes to glioblastoma eradication by combination immunovirotherapy and immune checkpoint blockade. Cancer Cell. 32:253–267.e5. 2017. View Article : Google Scholar : PubMed/NCBI

Liang Y, Wang B, Chen Q, Fu X, Jiang C, Lin Z, Zhuang Q, Zeng Y, Liu X and Zhang D: Systemic delivery of glycosylated-PEG-masked oncolytic virus enhances targeting of antitumor immuno-virotherapy and modulates T and NK cell infiltration. Theranostics. 13:5452–5468. 2023. View Article : Google Scholar : PubMed/NCBI

Patel MR, Dash A, Jacobson BA, Ji Y, Baumann D, Ismail K and Kratzke RA: JAK/STAT inhibition with ruxolitinib enhances oncolytic virotherapy in non-small cell lung cancer models. Cancer Gene Ther. 26:411–418. 2019. View Article : Google Scholar : PubMed/NCBI

Nguyen TT, Ramsay L, Ahanfeshar-Adams M, Lajoie M, Schadendorf D, Alain T and Watson IR: Mutations in the IFNγ-JAK-STAT pathway causing resistance to immune checkpoint inhibitors in melanoma increase sensitivity to oncolytic virus treatment. Clin Cancer Res. 27:3432–3442. 2021. View Article : Google Scholar : PubMed/NCBI

Lecoultre M, Walker PR and El Helali A: Oncolytic virus and tumor-associated macrophage interactions in cancer immunotherapy. Clin Exp Med. 24:2022024. View Article : Google Scholar : PubMed/NCBI

Fujikura Y, Kudlackova P, Vokurka M, Krijt J and Melkova Z: The effect of nitric oxide on vaccinia virus-encoded ribonucleotide reductase. Nitric Oxide. 20:114–121. 2009. View Article : Google Scholar

Pittet MJ, Michielin O and Migliorini D: Clinical relevance of tumour-associated macrophages. Nat Rev Clin Oncol. 19:402–421. 2022. View Article : Google Scholar : PubMed/NCBI

Meisen WH, Wohleb ES, Jaime-Ramirez AC, Bolyard C, Yoo JY, Russell L, Hardcastle J, Dubin S, Muili K, Yu J, et al: The impact of macrophage- and microglia-secreted TNFα on Oncolytic HSV-1 therapy in the glioblastoma tumor microenvironment. Clin Cancer Res. 21:3274–3285. 2015. View Article : Google Scholar : PubMed/NCBI

van den Bossche WBL, Kleijn A, Teunissen CE, Voerman JSA, Teodosio C, Noske DP, van Dongen JJM, Dirven CMF and Lamfers MLM: Oncolytic virotherapy in glioblastoma patients induces a tumor macrophage phenotypic shift leading to an altered glioblastoma microenvironment. Neuro Oncol. 20:1494–1504. 2018. View Article : Google Scholar : PubMed/NCBI

Kober C, Rohn S, Weibel S, Geissinger U, Chen NG and Szalay AA: Microglia and astrocytes attenuate the replication of the oncolytic vaccinia virus LIVP 1.1.1 in murine GL261 gliomas by acting as vaccinia virus traps. J Transl Med. 13:2162015. View Article : Google Scholar : PubMed/NCBI

Liu YP, Suksanpaisan L, Steele MB, Russell SJ and Peng KW: Induction of antiviral genes by the tumor microenvironment confers resistance to virotherapy. Sci Rep. 3:23752013. View Article : Google Scholar : PubMed/NCBI

Zhang Q and Liu F: Advances and potential pitfalls of oncolytic viruses expressing immunomodulatory transgene therapy for malignant gliomas. Cell Death Dis. 11:4852020. View Article : Google Scholar : PubMed/NCBI

Shen Z, Liu X, Fan G, Na J, Liu Q, Lin F, Zhang Z and Zhong L: Improving the therapeutic efficacy of oncolytic viruses for cancer: Targeting macrophages. J Transl Med. 21:8422023. View Article : Google Scholar : PubMed/NCBI

Blitz SE, Kappel AD, Gessler FA, Klinger NV, Arnaout O, Lu Y, Peruzzi PP, Smith TR, Chiocca EA, Friedman GK and Bernstock JD: Tumor-associated macrophages/microglia in glioblastoma oncolytic virotherapy: A double-edged sword. Int J Mol Sci. 23:18082022. View Article : Google Scholar : PubMed/NCBI

Ferguson MS, Chard Dunmall LS, Gangeswaran R, Marelli G, Tysome JR, Burns E, Whitehead MA, Aksoy E, Alusi G, Hiley C, et al: Transient inhibition of PI3Kδ enhances the therapeutic effect of intravenous delivery of oncolytic vaccinia virus. Mol Ther. 28:1263–1275. 2020. View Article : Google Scholar : PubMed/NCBI

Lee TJ, Nair M, Banasavadi-Siddegowda Y, Liu J, Nallanagulagari T, Jaime-Ramirez AC, Guo JY, Quadri H, Zhang J, Bockhorst KH, et al: Enhancing therapeutic efficacy of oncolytic herpes simplex virus-1 with integrin β1 blocking antibody OS2966. Mol Cancer Ther. 18:1127–1136. 2019. View Article : Google Scholar : PubMed/NCBI

Thorne AH, Meisen WH, Russell L, Yoo JY, Bolyard CM, Lathia JD, Rich J, Puduvalli VK, Mao H, Yu J, et al: Role of cysteine-rich 61 protein (CCN1) in macrophage-mediated oncolytic herpes simplex virus clearance. Mol Ther. 22:1678–1687. 2014. View Article : Google Scholar : PubMed/NCBI

Zhang KL, Li RP, Zhang BP, Gao ST, Li B, Huang CJ, Cao R, Cheng JY, Xie XD, Yu ZH and Feng XY: Efficacy of a new oncolytic adenovirus armed with IL-13 against oral carcinoma models. Onco Targets Ther. 12:6515–6523. 2019. View Article : Google Scholar : PubMed/NCBI

Hedrick CC and Malanchi I: Neutrophils in cancer: Heterogeneous and multifaceted. Nat Rev Immunol. 22:173–187. 2022. View Article : Google Scholar

Ng MSF, Kwok I, Tan L, Shi C, Cerezo-Wallis D, Tan Y, Leong K, Calvo GF, Yang K, Zhang Y, et al: Deterministic reprogramming of neutrophils within tumors. Science. 383:eadf64932024. View Article : Google Scholar : PubMed/NCBI

Andzinski L, Kasnitz N, Stahnke S, Wu CF, Gereke M, von Köckritz-Blickwede M, Schilling B, Brandau S, Weiss S and Jablonska J: Type I IFNs induce anti-tumor polarization of tumor associated neutrophils in mice and human. Int J Cancer. 138:1982–1993. 2016. View Article : Google Scholar

Naumenko V, Turk M, Jenne CN and Kim SJ: Neutrophils in viral infection. Cell Tissue Res. 371:505–516. 2018. View Article : Google Scholar : PubMed/NCBI

Taifour T, Attalla SS, Zuo D, Gu Y, Sanguin-Gendreau V, Proud H, Solymoss E, Bui T, Kuasne H, Papavasiliou V, et al: The tumor-derived cytokine Chi3l1 induces neutrophil extracellular traps that promote T cell exclusion in triple-negative breast cancer. Immunity. 56:2755–2772.e8. 2023. View Article : Google Scholar : PubMed/NCBI

He XY, Gao Y, Ng D, Michalopoulou E, George S, Adrover JM, Sun L, Albrengues J, Daßler-Plenker J, Han X, et al: Chronic stress increases metastasis via neutrophil-mediated changes to the microenvironment. Cancer Cell. 42:474–486.e12. 2024. View Article : Google Scholar : PubMed/NCBI

Zhou D, Zhang C, Sun J and Yuan M: Neutrophils in oncolytic virus immunotherapy. Front Immunol. 15:14904142024. View Article : Google Scholar : PubMed/NCBI

Dai W, Tian R, Yu L, Bian S, Chen Y, Yin B, Luan Y, Chen S, Fan Z, Yan R, et al: Overcoming therapeutic resistance in oncolytic herpes virotherapy by targeting IGF2BP3-induced NETosis in malignant glioma. Nat Commun. 15:1312024. View Article : Google Scholar : PubMed/NCBI

Price PJ, Luckow B, Torres-Domínguez LE, Brandmüller C, Zorn J, Kirschning CJ, Sutter G and Lehmann MH: Chemokine (C-C Motif) receptor 1 is required for efficient recruitment of neutrophils during respiratory infection with modified vaccinia virus Ankara. J Virol. 88:10840–10850. 2014. View Article : Google Scholar : PubMed/NCBI

West BC, Escheté ML, Cox ME and King JW: Neutrophil uptake of vaccinia virus in vitro. J Infect Dis. 156:597–606. 1987. View Article : Google Scholar : PubMed/NCBI

Breitbach CJ, Paterson JM, Lemay CG, Falls TJ, McGuire A, Parato KA, Stojdl DF, Daneshmand M, Speth K, Kirn D, et al: Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow. Mol Ther. 15:1686–1693. 2007. View Article : Google Scholar : PubMed/NCBI

Taipale K, Liikanen I, Koski A, Heiskanen R, Kanerva A, Hemminki O, Oksanen M, Grönberg-Vähä-Koskela S, Hemminki K, Joensuu T and Hemminki A: Predictive and prognostic clinical variables in cancer patients treated with adenoviral oncolytic immunotherapy. Mol Ther. 24:1323–1332. 2016. View Article : Google Scholar : PubMed/NCBI

He CB and Lin XJ: Inflammation scores predict the survival of patients with hepatocellular carcinoma who were treated with transarterial chemoembolization and recombinant human type-5 adenovirus H101. PLoS One. 12:e01747692017. View Article : Google Scholar : PubMed/NCBI

Zhou D, Xu W, Ding X, Guo H, Wang J, Zhao G, Zhang C, Zhang Z, Wang Z, Wang P, et al: Transient inhibition of neutrophil functions enhances the antitumor effect of intravenously delivered oncolytic vaccinia virus. Cancer Sci. 115:1129–1140. 2024. View Article : Google Scholar : PubMed/NCBI

Fu X, Tao L, Rivera A, Xu H and Zhang X: Virotherapy induces massive infiltration of neutrophils in a subset of tumors defined by a strong endogenous interferon response activity. Cancer Gene Ther. 18:785–794. 2011. View Article : Google Scholar : PubMed/NCBI

Minott JA, van Vloten JP, Chan L, Mehrani Y, Bridle BW and Karimi K: The role of neutrophils in oncolytic orf virus-mediated cancer immunotherapy. Cells. 11:28582018. View Article : Google Scholar

Liu Y, Xu C, Xiao X, Chen Y, Wang X, Liu W, Tan Y, Zhu W, Hu J, Liang J, et al: Overcoming resistance to oncolytic virus M1 by targeting PI3K-γ in tumor-associated myeloid cells. Mol Ther. 30:3677–3693. 2022. View Article : Google Scholar : PubMed/NCBI

Bulstrode H, Girdler GC, Gracia T, Aivazidis A, Moutsopoulos I, Young AMH, Hancock J, He X, Ridley K, Xu Z, et al: Myeloid cell interferon secretion restricts Zika flavivirus infection of developing and malignant human neural progenitor cells. Neuron. 110:3936–3951.e10. 2022. View Article : Google Scholar : PubMed/NCBI

Noh MH, Kang JM, Miller AA, Nguyen G, Huang M, Shim JS, Bueso-Perez AJ, Murphy SA, Rivera-Caraballo KA, Otani Y, et al: Targeting IGF2 to reprogram the tumor microenvironment for enhanced viro-immunotherapy. Neuro Oncol. 26:1602–1616. 2024. View Article : Google Scholar : PubMed/NCBI

Bald T, Krummel MF, Smyth MJ and Barry KC: The NK cell-cancer cycle: Advances and new challenges in NK cell-based immunotherapies. Nat Immunol. 21:835–847. 2020. View Article : Google Scholar : PubMed/NCBI

Alvarez-Breckenridge CA, Yu J, Price R, Wojton J, Pradarelli J, Mao H, Wei M, Wang Y, He S, Hardcastle J, et al: NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors. Nat Med. 18:1827–1834. 2012. View Article : Google Scholar : PubMed/NCBI

Reale A, Gatta A, Shaik AKB, Shallak M, Chiaravalli AM, Cerati M, Zaccaria M, La Rosa S, Calistri A, Accolla RS and Forlani G: An oncolytic HSV-1 vector induces a therapeutic adaptive immune response against glioblastoma. J Transl Med. 22:8622024. View Article : Google Scholar : PubMed/NCBI

Kim Y, Yoo JY, Lee TJ, Liu J, Yu J, Caligiuri MA, Kaur B and Friedman A: Complex role of NK cells in regulation of oncolytic virus-bortezomib therapy. Proc Natl Acad Sci USA. 115:4927–4932. 2018. View Article : Google Scholar : PubMed/NCBI

Varudkar N, Oyer JL, Copik A and Parks GD: Oncolytic parainfluenza virus combines with NK cells to mediate killing of infected and non-infected lung cancer cells within 3D spheroids: role of type I and type III interferon signaling. J Immunother Cancer. 9:e0023732021. View Article : Google Scholar : PubMed/NCBI

Wang Y, Jin J, Li Y, Zhou Q, Yao R, Wu Z, Hu H, Fang Z, Dong S, Cai Q, et al: NK cell tumor therapy modulated by UV-inactivated oncolytic herpes simplex virus type 2 and checkpoint inhibitors. Transl Res. 240:64–86. 2022. View Article : Google Scholar

Yan Y, Li S, Jia T, Du X, Xu Y, Zhao Y, Li L, Liang K, Liang W, Sun H and Li R: Combined therapy with CTL cells and oncolytic adenovirus expressing IL-15-induced enhanced antitumor activity. Tumour Biol. 36:4535–4543. 2015. View Article : Google Scholar : PubMed/NCBI

Alvarez-Breckenridge CA, Yu J, Price R, Wei M, Wang Y, Nowicki MO, Ha YP, Bergin S, Hwang C, Fernandez SA, et al: The histone deacetylase inhibitor valproic acid lessens NK cell action against oncolytic virus-infected glioblastoma cells by inhibition of STAT5/T-BET signaling and generation of gamma interferon. J Virol. 86:4566–4577. 2012. View Article : Google Scholar : PubMed/NCBI

Altomonte J, Wu L, Meseck M, Chen L, Ebert O, Garcia-Sastre A, Fallon J, Mandeli J and Woo SL: Enhanced oncolytic potency of vesicular stomatitis virus through vector-mediated inhibition of NK and NKT cells. Cancer Gene Ther. 16:266–278. 2009. View Article : Google Scholar

Han J, Chen X, Chu J, Xu B, Meisen WH, Chen L, Zhang L, Zhang J, He X, Wang QE, et al: TGFβ treatment enhances glioblastoma virotherapy by inhibiting the innate immune response. Cancer Res. 75:5273–5282. 2015. View Article : Google Scholar : PubMed/NCBI

Kurmasheva N, Said A, Wong B, Kinderman P, Han X, Rahimic AHF, Kress A, Carter-Timofte ME, Holm E, van der Horst D, et al: Octyl itaconate enhances VSVdelta51 oncolytic virotherapy by multitarget inhibition of antiviral and inflammatory pathways. Nat Commun. 15:40962024. View Article : Google Scholar

Taverner WK, Jacobus EJ, Christianson J, Champion B, Paton AW, Paton JC, Su W, Cawood R, Seymour LW and Lei-Rossmann J: Calcium influx caused by ER stress inducers enhances oncolytic adenovirus enadenotucirev replication and killing through PKCα activation. Mol Ther Oncolytics. 15:117–130. 2019. View Article : Google Scholar :

Bhatt DK, Janzen T, Daemen T and Weissing FJ: Modelling the spatial dynamics of oncolytic virotherapy in the presence of virus-resistant tumour cells. PLoS Comput Biol. 18:e10100762022. View Article : Google Scholar : PubMed/NCBI

Kloker LD, Yurttas C and Lauer UM: Three-dimensional tumor cell cultures employed in virotherapy research. Oncolytic Virother. 7:79–93. 2018. View Article : Google Scholar : PubMed/NCBI

Brachtlova T, Li J, van der Meulen-Muileman IH, Sluiter F, von Meijenfeldt W, Witte I, Massaar S, van den Oever R, de Vrij J and van Beusechem VW: Quantitative virus-associated RNA detection to monitor oncolytic adenovirus replication. Int J Mol Sci. 25:65512024. View Article : Google Scholar : PubMed/NCBI

Karnik I, Her Z, Neo SH, Liu WN and Chen Q: Emerging preclinical applications of humanized mouse models in the discovery and validation of novel immunotherapeutics and their mechanisms of action for improved cancer treatment. Pharmaceutics. 15:16002023. View Article : Google Scholar : PubMed/NCBI

Ambegoda P, Wei HC and Jang SR: The role of immune cells in resistance to oncolytic viral therapy. Math Biosci Eng. 21:5900–5946. 2024. View Article : Google Scholar : PubMed/NCBI

West J, Robertson-Tessi M and Anderson ARA: Agent-based methods facilitate integrative science in cancer. Trends Cell Biol. 33:300–311. 2023. View Article : Google Scholar

Sachak-Patwa R, Lafferty EI, Schmit CJ, Thompson RN and Byrne HM: A target-cell limited model can reproduce influenza infection dynamics in hosts with differing immune responses. J Theor Biol. 567:1114912023. View Article : Google Scholar : PubMed/NCBI